Lupin Q4 FY26 PAT jumps 88%; EBITDA margin hits 35.5%

What Lupin reported for the March 2026 quarter

Lupin Ltd posted a sharp jump in profitability for the quarter ended 31 March 2026 (Q4 FY26), supported by higher sales and improved operating leverage across key markets. Consolidated profit after tax (PAT) rose to Rs 1,468.70 crore, up 87.72% from Rs 782.40 crore in Q4 FY25. PAT also increased 24.42% sequentially from Rs 1,180.50 crore in Q3 FY26. Net sales grew 32.9% year on year to Rs 7,391.91 crore from Rs 5,562.20 crore, and was up 4.1% from Rs 7,100.50 crore in Q3 FY26.

Margins and operating leverage stood out in Q4

Operating performance improved materially in Q4 FY26. EBITDA rose 90.57% year on year to Rs 2,626.30 crore from Rs 1,378.10 crore, and was up 10.51% versus Rs 2,376.60 crore in Q3 FY26. EBITDA margin expanded 1,070 basis points year on year to 35.5% from 24.8%, and improved 200 basis points sequentially from 33.5%. Gross profit (excluding other operating income) increased 42.90% to Rs 5,540.30 crore. Gross margin improved to 75% from 69.7% a year ago and 73.5% in the prior quarter.

Profit before tax, forex gains, and exceptional items

Profit before tax (PBT) climbed to Rs 1,928 crore in Q4 FY26, up 115.22% from Rs 895.80 crore in Q4 FY25. PBT was also higher by 26.68% from Rs 1,522 crore in Q3 FY26. During the quarter, other income rose to Rs 140.70 crore, up 146.84% year on year. Lupin also reported a forex gain of Rs 314.50 crore compared with a forex gain of Rs 29.10 crore in Q4 FY25. Exceptional items stood at Rs 131.30 crore in Q4 FY26 versus nil in the corresponding quarter last year.

Regional performance: US led, India steady, emerging markets strong

The US remained Lupin’s largest contributor in Q4 FY26. US revenue increased 56.90% year on year to Rs 3,398.70 crore. India sales rose 11.51% to Rs 1,908.20 crore, while emerging markets revenue jumped 49.21% to Rs 990.60 crore. Other developed markets revenue increased 7.15% to Rs 845.30 crore. Separately, the company’s US business was described as having sales of USD 130 crore (USD 1.3 billion), up 40% year on year, supported by new product launches.

Product mix, costs, and R&D spending

Total formulations sales grew 34% year on year to Rs 7,142.80 crore, while API revenue increased 7.60% to Rs 249.10 crore. Material cost rose 9.81% to Rs 1,851.60 crore and employee cost increased 24.11% to Rs 1,242.70 crore. Manufacturing and other expenses climbed 30.91% to Rs 2,209.30 crore. Research and development spending for Q4 FY26 was Rs 589.80 crore, which the company said was 8.0% of sales. In other disclosures, Lupin’s R&D spend was also referenced at 7.5% of sales, aligned to its focus on complex and specialty platforms and a pipeline of over 50 active products.

Full-year FY26 snapshot: growth across profit metrics

For the full year ended 31 March 2026, net sales increased 23.9% to Rs 27,487.50 crore from Rs 22,192.10 crore in FY25. PBT rose 71.17% to Rs 6,872.60 crore, while PAT increased 61.98% to Rs 5,355.50 crore. Full-year EBITDA jumped 68.64% to Rs 9,240.50 crore, and EBITDA margin expanded to 33.6% from 24.7%. Net cash from operating activities rose to Rs 7,334.50 crore in FY26 from Rs 2,999.94 crore in FY25.

Balance sheet, capex, and working capital position

Lupin reported operating working capital of Rs 7,132.40 crore as of quarter-end, with operating days at 87. Capital expenditure was Rs 305.20 crore in Q4 FY26, and Rs 1,061.80 crore for the full year. The company reported net debt of negative Rs 4,635.80 crore as of 31 March 2026, indicating a net cash position. Net debt-to-equity ratio was negative 0.21.

Management commentary and strategic direction

Managing Director Nilesh Gupta said Q4 and FY26 performance reflected strong sales growth and margin expansion in the US and India markets, supported by investments in technology, execution, and operational efficiencies. The company reported a strong launch in India, with Lupin becoming a top player in the generic semaglutide market. Lupin also said it plans to expand into South Africa, Brazil, and Canada, with launches expected in the current and next fiscal years. Separately, CEO Vinita Gupta highlighted plans for multiple launches over the next few years, with a focus on injectables, respiratory products, and biosimilars.

Key risks the company and analysts flagged

Lupin anticipated increased competition for key products such as tolvaptan and mirabegron, with potential revenue erosion in the US market due to price declines. EBITDA margins are expected to decrease to around 25% in FY27, down from 29.7% in FY26, due to competitive pressure and higher R&D spending. The company also flagged inflationary pressures affecting freight and raw material costs as a profitability risk. Another operational risk mentioned was difficulty in achieving product PK for certain respiratory products, which can delay filing timelines. Lupin also cited a mirabegron settlement involving a USD 9 crore (USD 90 million) payout, while Ramesh Swaminathan explained a USD 1.5 crore (USD 15 million) provision linked to past expenses and USD 7.5 crore (USD 75 million) linked to future market presence.

Market reaction and what investors watched

Despite the strong headline growth, Lupin shares fell 3.51% to Rs 2,373.50 on the BSE after the results. The update landed alongside mixed investor focus: strong US-led execution in Q4, but also the outlook for FY27 and beyond as competition rises and R&D intensity increases. Analysts at BNP Paribas India were cited as expecting higher competition in FY27/28 for a few key US products supporting growth. In India, the company reported outperformance in its core prescription business in some commentary, but also noted that lower local tender sales affected overall India business growth.

Key numbers at a glance

Conclusion

Lupin’s Q4 FY26 performance showed strong sales momentum and a step-up in profitability, led by the US market and supported by higher margins. At the same time, management and external commentary pointed to rising competitive intensity in the US and higher R&D spend as key variables for FY27. Investors are likely to track execution on upcoming launches, progress in respiratory filings, and how pricing trends evolve in key US products. Any further guidance and medium-term margin commentary, where provided by the company, will remain central to how the market assesses sustainability after a strong FY26 finish.